ACE-031, at a strength of 1mg, is presently generating considerable interest across Europe. Early clinical trials in nations such as Germany and its surrounding areas, France and its neighbors, and the UK have revealed promising results in treating certain brain disorders. Regulatory bodies across the continent are carefully assessing the inform… Read More